Evoke Pharma Inc. (NASDAQ:EVOK) shares gapped up before the market opened on Friday . The stock had previously closed at $2.71, but opened at $3.03. Evoke Pharma shares last traded at $3.86, with a volume of 20,582,656 shares.

Several research analysts have recently commented on EVOK shares. FBR & Co restated a “buy” rating on shares of Evoke Pharma in a research note on Saturday, May 14th. Brean Capital restated a “buy” rating on shares of Evoke Pharma in a research note on Thursday, May 12th. Rodman & Renshaw reiterated a “buy” rating on shares of Evoke Pharma in a research note on Thursday, May 12th. Noble Financial lowered shares of Evoke Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, July 19th. Finally, Zacks Investment Research lowered shares of Evoke Pharma from a “buy” rating to a “hold” rating in a research note on Monday, May 16th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $13.34.

The firm’s 50 day moving average price is $5.82 and its 200 day moving average price is $4.73. The company’s market capitalization is $18.97 million.

Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings results on Wednesday, May 11th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.41) by $0.04. On average, analysts predict that Evoke Pharma Inc. will post ($1.43) earnings per share for the current year.

In other news, major shareholder Parters Vii L. P. Domain sold 344,120 shares of the business’s stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $4.70, for a total value of $1,617,364.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.